Trametinib (Mekinist): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in BRAF V600–Mutated Cancers

Trametinib (Mekinist) is an oral, selective inhibitor of MEK1 and MEK2, key kinases within the RAS–RAF–MEK–ERK/MAPK signaling pathway. By blocking MEK activation and downstream ERK signaling, trametinib suppresses tumor-cell proliferation and survival in cancers driven by MAPK-pathway activation.

Although trametinib is FDA approved as a single agent for BRAF-inhibitor–naïve patients with unresectable or metastatic BRAF V600E/K-mutated melanoma, its major contemporary role is in combination with dabrafenib. The dabrafenib/trametinib combination is FDA approved across several BRAF V600E-driven malignancies, including melanoma, metastatic NSCLC, anaplastic thyroid cancer, tumor-agnostic solid tumors, and pediatric low-grade glioma.

Key Facts

• Generic name: Trametinib
• Brand name: Mekinist
• Drug class: MEK1/MEK2 inhibitor
• Route: Oral
• Initial US approval: 2013
• Primary targets: MEK1 and MEK2
• Adult dose: 2 mg orally once daily
• Administration: At least 1 hour before or at least 2 hours after a meal
• Tablet strengths: 0.5 mg and 2 mg
• Additional formulation: Powder for oral solution
• Most common partner: Dabrafenib
• Major FDA indications: Melanoma, metastatic NSCLC, anaplastic thyroid cancer, BRAF V600E-positive solid tumors, pediatric low-grade glioma
• Important toxicities: Cardiomyopathy, hemorrhage, venous thromboembolism, ocular toxicity, ILD/pneumonitis, severe febrile reactions, serious skin toxicity, hyperglycemia, and GI perforation/colitis
• Current US status: FDA approved.

What Is Trametinib?

Trametinib is a small-molecule inhibitor of:

MEK1 and MEK2

also known as:

MAP2K1 and MAP2K2.

MEK1/2 are central components of the:

RAS → RAF → MEK → ERK

signaling cascade.

Normally, this pathway helps regulate:

• Cellular proliferation
• Differentiation
• Survival
• Migration

In BRAF V600-mutated tumors, constitutively active BRAF continuously stimulates MEK and ERK.

This persistent signaling contributes to uncontrolled malignant growth.

Trametinib interrupts the pathway downstream of BRAF.

What Is the Mechanism of Action of Trametinib?

1. MAPK-Pathway Activation Drives Tumor Growth

Activating mutations such as:

BRAF V600E

or:

BRAF V600K

produce constitutive activation of BRAF.

Mutant BRAF continuously stimulates:

MEK1/2.

2. Activated MEK Phosphorylates ERK

MEK1/2 phosphorylate:

ERK1/2

which then regulate multiple transcriptional programs promoting:

• Cell-cycle progression
• Tumor-cell proliferation
• Survival
• Migration
• Resistance to apoptosis

3. Trametinib Selectively Inhibits MEK1 and MEK2

Trametinib is an:

Allosteric, reversible MEK1/2 inhibitor.

Unlike ATP-competitive kinase inhibitors, trametinib binds MEK at a site distinct from the ATP-binding pocket.

It inhibits both:

• MEK activation
• MEK kinase activity

thereby reducing phosphorylation of ERK.

4. ERK Signaling Is Suppressed

Reduced ERK activation decreases downstream transcriptional signaling associated with:

• Proliferation
• Growth
• Survival

5. Tumor Growth Is Reduced

The downstream effects include:

• Reduced tumor-cell proliferation
• Reduced survival signaling
• Increased apoptosis
• Tumor regression in MAPK-dependent cancers

The mechanism can be summarized as:

Trametinib → MEK1/2 inhibition → reduced ERK phosphorylation → MAPK-pathway suppression → decreased tumor-cell proliferation and survival.

Why Is Trametinib Commonly Combined With Dabrafenib?

Dabrafenib inhibits:

Mutant BRAF

while trametinib inhibits:

MEK1/2 downstream of BRAF.

Therefore:

Dabrafenib + trametinib

creates dual MAPK-pathway blockade.

This strategy helps:

• Produce deeper pathway suppression
• Delay MAPK reactivation
• Improve response durability
• Extend progression-free survival
• Improve overall survival
• Reduce some paradoxical BRAF-inhibitor–associated secondary skin tumors

The combination has become more clinically important than trametinib monotherapy in most BRAF V600-driven cancers.

What Is the Dose of Trametinib?

Adults

The recommended adult dose is:

2 mg orally once daily. 

It should be taken approximately:

24 hours apart

at the same time each day.

Treatment continues until:

• Disease progression
• Unacceptable toxicity

depending on the indication.

How Should Trametinib Be Taken?

Trametinib should be taken:

At least 1 hour before or at least 2 hours after a meal. 

Tablets should:

• Be swallowed whole
• Not be crushed
• Not be broken

The once-daily schedule should be maintained consistently.

What If a Dose Is Missed?

Do not take a missed dose if the next scheduled dose is due within:

12 hours.

If more than 12 hours remain, the missed dose may be taken.

If vomiting occurs after taking trametinib:

Do not take an additional dose.

Take the next dose at the scheduled time.

How Are Trametinib Dose Reductions Made?

For adults receiving:

2 mg once daily

the first dose reduction is:

1.5 mg once daily.

The second reduction is:

1 mg once daily.

If trametinib cannot be tolerated after the permitted dose reductions:

Permanently discontinue treatment. 

Dose modification may be needed for:

• Cardiomyopathy
• Hemorrhage
• Venous thromboembolism
• Ocular toxicity
• ILD/pneumonitis
• Severe skin toxicity
• Pyrexia when used with dabrafenib
• Other Grade ≥3 adverse events

Pediatric Dosing

Trametinib is approved in selected pediatric BRAF V600E-positive indications beginning at:

1 year of age.

For tablets in patients weighing at least 26 kg:

• 26–37 kg: 1 mg once daily
• 38–50 kg: 1.5 mg once daily
• ≥51 kg: 2 mg once daily.

For smaller children or patients requiring finer weight-based dosing, an:

Oral solution

is available.

The oral solution allows dosing beginning at lower body weights according to the prescribing-information table.

What Formulations Are Available?

Trametinib is available as:

Tablets

• 0.5 mg
• 2 mg

Oral Solution

Mekinist powder for oral solution is reconstituted to provide:

0.05 mg/mL

and can be administered:

• Orally
• Through an appropriate feeding tube

after proper preparation.

Does Trametinib Require Renal or Hepatic Dose Adjustment?

Renal Impairment

No clinically meaningful pharmacokinetic effect has generally been observed in:

• Mild renal impairment
• Moderate renal impairment

Evidence is more limited in:

Severe renal impairment.

Hepatic Impairment

Mild hepatic impairment does not generally require routine dose adjustment.

Patients with moderate or severe hepatic impairment require additional caution because available evidence is limited and exposure may be altered.

What Is the Pharmacokinetic Profile of Trametinib?

Absorption

Trametinib is absorbed orally and reaches maximum plasma concentrations within several hours.

Food decreases trametinib exposure, which explains the recommendation to administer it:

At least 1 hour before or 2 hours after a meal.

Protein Binding

Trametinib is:

Highly protein bound.

Half-Life

Trametinib has a particularly long terminal half-life of approximately:

4–5 days.

This allows:

Once-daily dosing.

Metabolism

Unlike many TKIs, trametinib does not depend predominantly on CYP3A metabolism.

Its metabolism primarily involves:

• Deacetylation
• Oxidation
• Glucuronidation

Therefore, its interaction profile differs from that of dabrafenib.

What Are the Clinical Uses of Trametinib?

1. BRAF V600E/K-Mutated Unresectable or Metastatic Melanoma

Trametinib is FDA approved:

As a single agent

for BRAF-inhibitor–naïve patients with unresectable or metastatic melanoma harboring:

• BRAF V600E
• BRAF V600K

mutations.

It is also approved:

In combination with dabrafenib.

2. Adjuvant BRAF V600E/K-Mutated Melanoma

Trametinib plus dabrafenib is approved as:

Adjuvant therapy after complete resection

for melanoma with:

• BRAF V600E
• BRAF V600K

mutation and lymph-node involvement.

Treatment may continue for up to:

1 year

unless recurrence or unacceptable toxicity occurs.

3. BRAF V600E-Mutated Metastatic NSCLC

Trametinib plus dabrafenib is FDA approved for:

Metastatic NSCLC with BRAF V600E mutation. 

4. BRAF V600E-Mutated Anaplastic Thyroid Cancer

The combination is approved for:

Locally advanced or metastatic BRAF V600E-mutated anaplastic thyroid cancer

when no satisfactory locoregional treatment options exist.

5. Tumor-Agnostic BRAF V600E-Positive Solid Tumors

Trametinib plus dabrafenib is approved for:

Adults and pediatric patients ≥1 year with unresectable or metastatic BRAF V600E-positive solid tumors

that:

• Progressed after previous treatment
• Have no satisfactory alternative treatment options

This indication remains:

Accelerated approval. 

Important limitation:

The combination is not indicated for colorectal cancer because of intrinsic resistance to isolated BRAF/MEK pathway inhibition in CRC. 

6. Pediatric BRAF V600E-Mutated Low-Grade Glioma

Trametinib plus dabrafenib is approved for:

Children aged 1 year and older with BRAF V600E-mutated low-grade glioma requiring systemic therapy. 

What Did Trametinib Clinical Trials Show?

METRIC — Trametinib Monotherapy in Metastatic Melanoma

The phase III METRIC trial evaluated trametinib versus chemotherapy in patients with:

BRAF V600E/K-mutated unresectable or metastatic melanoma.

A total of:

322 patients

were randomized:

Trametinib: 214
Chemotherapy: 108.

Median Progression-Free Survival

Initial analysis showed:

• Trametinib: 4.8 months
• Chemotherapy: 1.5 months

Hazard ratio:

0.45

P < 0.001.

Overall Survival

At 6 months:

• Trametinib: 81%
• Chemotherapy: 67%

despite substantial crossover.

Hazard ratio for death:

0.54.

Long-term follow-up confirmed a median PFS of approximately:

• 4.9 months
• 1.5 months, respectively.

COMBI-d and COMBI-v — Dabrafenib + Trametinib

The major modern role of trametinib was established by studies combining it with dabrafenib.

Pooled long-term data from:

• COMBI-d
• COMBI-v

included:

563 patients

who received dabrafenib plus trametinib.

5-Year Progression-Free Survival
19%.

5-Year Overall Survival
34%.

Complete Responses

Complete response occurred in approximately:

19%

of patients.

Among patients achieving complete response:

5-year OS reached approximately 71%.

These results established dual BRAF/MEK inhibition as a major targeted strategy in BRAF V600-mutated advanced melanoma.

COMBI-AD — Adjuvant Melanoma

COMBI-AD evaluated:

Dabrafenib + trametinib for 1 year

versus placebo after complete resection of high-risk:

Stage III BRAF V600E/K-mutated melanoma.

At nearly 10 years of follow-up:

Relapse-Free Survival

Hazard ratio:

0.52.

Distant Metastasis-Free Survival

Hazard ratio:

0.56.

The overall survival analysis showed an approximately:

20% reduction in the risk of death

but did not cross the predefined threshold for statistical significance.

Among patients with:

BRAF V600E

there was a numerically stronger OS benefit.

BRAF V600E-Mutated NSCLC

The phase II study of dabrafenib plus trametinib included both:

• Previously treated
• Previously untreated

patients with metastatic BRAF V600E-mutated NSCLC.

In previously untreated patients:

36 patients

received:

• Dabrafenib 150 mg twice daily
• Trametinib 2 mg once daily.

The study demonstrated a high objective response rate and durable disease control, supporting the FDA-approved use of the combination.

The previously treated cohort likewise demonstrated substantial antitumor activity.

ROAR — Anaplastic Thyroid Cancer and Rare Tumors

The ROAR basket study evaluated dabrafenib plus trametinib across several BRAF V600E-mutated rare cancers.

In anaplastic thyroid cancer, the combination produced clinically meaningful and often rapid responses, establishing BRAF/MEK inhibition as an important treatment for this historically difficult-to-treat cancer. PubMed

Pediatric BRAF V600E-Mutated Low-Grade Glioma

A randomized phase II trial compared:

Dabrafenib + trametinib

with:

Carboplatin + vincristine

as first-line systemic therapy in pediatric BRAF V600-mutated low-grade glioma.

The targeted-therapy combination produced:

• Significantly more objective responses
• Longer progression-free survival
• A more favorable safety profile

than conventional chemotherapy.

Earlier pediatric studies also established weight-based trametinib dosing and showed activity both as monotherapy and in combination with dabrafenib.

Is Trametinib FDA Approved?

Yes.

Trametinib received its initial US approval in:

2013.

Current FDA-approved uses include:

As Single-Agent Therapy

• BRAF-inhibitor–naïve BRAF V600E/K-mutated unresectable or metastatic melanoma

With Dabrafenib

• Unresectable/metastatic BRAF V600E/K melanoma
• Adjuvant BRAF V600E/K melanoma
• BRAF V600E metastatic NSCLC
• BRAF V600E locally advanced/metastatic anaplastic thyroid cancer
• BRAF V600E unresectable/metastatic solid tumors
• Pediatric BRAF V600E low-grade glioma.

What Is the Current Clinical Role of Trametinib?

Melanoma

Trametinib monotherapy remains FDA approved, but modern practice generally favors:

BRAF + MEK combination therapy

when targeted treatment is selected.

Dabrafenib + trametinib provides more durable pathway blockade than either agent alone.

Immune checkpoint therapy also plays a central role in advanced melanoma, so sequencing depends on:

• Disease burden
• Symptoms
• LDH
• CNS involvement
• Prior immunotherapy
• Need for rapid tumor shrinkage

NSCLC

Trametinib is not used as isolated MEK inhibition in BRAF V600E NSCLC.

Its clinically established role is:

Trametinib + dabrafenib

for BRAF V600E-mutated metastatic NSCLC.

Read more: OncoDaily’s review of BRAF V600E-mutated NSCLC, including the role of dabrafenib + trametinib and how targeted therapy compares with immunotherapy in current practice.

Watch more: Explore OncoDaily’s discussion on targeted therapy in BRAF-driven cancers and the evolving role of BRAF/MEK combinations.

Anaplastic Thyroid Cancer

In BRAF V600E-mutated ATC, dabrafenib plus trametinib can produce rapid tumor regression and remains one of the most important targeted options available.

Pediatric Low-Grade Glioma

Trametinib has become particularly important in pediatric neuro-oncology.

For BRAF V600E-mutated LGG requiring systemic treatment:

Dabrafenib + trametinib

is an established molecularly targeted option for children aged:

1 year and older. 

What Are the Major Side Effects of Trametinib?

When used as monotherapy, the most common adverse reactions include:

• Rash
• Diarrhea
• Lymphedema.

When combined with dabrafenib, common toxicities include:

• Pyrexia
• Nausea
• Rash
• Chills
• Diarrhea
• Vomiting
• Fatigue
• Headache
• Arthralgia
• Myalgia
• Peripheral edema.

Cardiomyopathy

Trametinib can reduce:

Left ventricular ejection fraction.

LVEF should be assessed:

• Before treatment
• Approximately 1 month after treatment begins
• Every 2–3 months thereafter. 

Clinically significant cardiomyopathy may require:

• Treatment interruption
• Dose reduction
• Permanent discontinuation

Ocular Toxicity

Important ocular adverse effects include:

• Retinal vein occlusion
• Retinal pigment epithelial detachment
• Other visual disturbances

Any new visual symptoms require:

Prompt ophthalmologic evaluation.

For confirmed:

Retinal vein occlusion

trametinib should be:

Permanently discontinued.

Interstitial Lung Disease/Pneumonitis

Patients should be monitored for:

• New cough
• Dyspnea
• Hypoxia
• New pulmonary infiltrates

For unexplained new or worsening respiratory symptoms:

Withhold trametinib.

Confirmed treatment-related ILD/pneumonitis requires:

Permanent discontinuation. 

Hemorrhage

Major hemorrhagic events can occur.

Patients should be assessed for:

• Gastrointestinal bleeding
• Intracranial hemorrhage
• Other clinically significant bleeding

Grade 4 hemorrhage generally requires:

Permanent discontinuation.

Venous Thromboembolism

Trametinib can increase the risk of:

• Deep-vein thrombosis
• Pulmonary embolism

Patients should be educated to report:

• Leg swelling
• Sudden chest pain
• Dyspnea
• Tachycardia

Life-threatening pulmonary embolism requires permanent discontinuation.

Colitis and Gastrointestinal Perforation

Although uncommon, trametinib can cause:

• Colitis
• Gastrointestinal perforation

Patients with:

• Severe abdominal pain
• Persistent diarrhea
• Peritoneal symptoms

require prompt evaluation.

Serious Febrile Reactions

When combined with dabrafenib:

Pyrexia is particularly characteristic.

Severe febrile reactions may be accompanied by:

• Rigors
• Dehydration
• Hypotension
• Renal impairment

Treatment interruption and supportive care may be necessary.

Serious Skin Toxicity

Trametinib can cause:

• Severe rash
• Secondary skin infection
• Severe cutaneous adverse reactions

Treatment should be permanently discontinued for:

• Severe cutaneous adverse reactions
• Grade 3–4 rash not improving adequately despite interruption.

Hyperglycemia

Trametinib can worsen:

Serum glucose control, particularly when used with dabrafenib.

Patients with:

• Diabetes
• Pre-existing hyperglycemia

should undergo glucose monitoring.

Hemophagocytic Lymphohistiocytosis

A rare but serious risk is:

Hemophagocytic lymphohistiocytosis (HLH).

If HLH is suspected:

Interrupt therapy.

If confirmed:

Discontinue trametinib.

What Monitoring Is Required?

Monitoring during trametinib treatment should include:

• LVEF before treatment
• LVEF after approximately 1 month
• LVEF every 2–3 months thereafter
• Visual symptoms
• Ophthalmologic assessment when indicated
• Respiratory symptoms
• Signs of ILD/pneumonitis
• Signs of hemorrhage
• Signs of DVT/PE
• Skin toxicity
• Temperature when combined with dabrafenib
• Hydration status
• Blood glucose
• Liver tests as clinically appropriate
• GI symptoms suggesting colitis or perforation
• Symptoms suggesting HLH

Particular attention should be given to:

Cardiac function, ocular toxicity, respiratory symptoms, bleeding, thromboembolism, fever, and skin toxicity.